OmniAb, Inc.

Listed Company

OABIWCIK 0001846253NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthServices-Commercial Physical & Biological ResearchDelawareFY ends Dec 31

Period

FY 2025

Revenue

$18.67M

Net Income

$-64.78M

Total Assets

$300.91M

Equity

$267.03M

Shares Out

144.78M

Op. Cash Flow

$-36.45M

Business

OmniAb, Inc. licenses an integrated antibody discovery platform to pharmaceutical and biotechnology companies and academic institutions to enable the discovery of next-generation therapeutic antibodies using proprietary engineered transgenic animals. It offers transgenic animal platforms (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniFlic, OmniClic, OmnidAb), high-throughput single B‑cell screening technologies (xPloration, GEM), computational antigen design, OmniDeep AI tools, and the OmniHub bioinformatics portal. Key business activities include platform licensing, research services and screening, antigen production and ion channel discovery capabilities, and partnership-based milestone and royalty arrangements. OmniAb distributes its technologies and services to global pharmaceutical, biotech and academic partners and integrates with partners’ internal or external workflows via license agreements and secure data portals.

Summary from filing dated 2025-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	19	26	34	59	35
Research and development	48	55	57	48	39
General and administrative	29	31	33	25	17
Amortization of intangibles	13	17	14	13	13
Other operating income, net	−3	−2	191,000	−592,000	1
Total costs and operating expenses	88	101	104	86	70
Loss from operations	−69	−75	−69	−27	−36
Interest income	3	3	5	587,000	0
Other income (expense), net	15,000	−15,000	1,000	0	1
Total other income (expense), net	3	3	5	587,000	1
Loss before income taxes	−66	−71	−64	−26	−34
Income tax benefit	2	9	14	4	7
Net loss	−65	−62	−51	−22	−27
Net loss per share, basic (dollars per share)	−0.57	−0.61	−0.51	−0.26	−0.33
Net loss per share, diluted (dollars per share)	−0.57	−0.61	−0.51	−0.26	−0.33
Weighted-average shares outstanding, basic (in shares)	114	102	100	85	83
Weighted-average shares outstanding, diluted (in shares)	114	102	100	85	83

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-10-31
Cash and cash equivalents	26	28	16	33	98
Short-term investments	29	32	71	55	—
Accounts receivable, net	7	5	4	30	—
Prepaid expenses and other current assets	4	3	4	6	2
Total current assets	65	68	95	125	100
Intangible assets, net	125	138	155	167	166
Goodwill	84	84	84	84	84
Property and equipment, net	9	15	18	20	20
Operating lease right-of-use assets	16	18	20	21	21
Restricted cash	560,000	560,000	560,000	—	—
Other long-term assets	912,000	2	2	3	1
Total assets	301	326	375	421	393
Accounts payable	2	2	4	3	473,000
Accrued expenses and other current liabilities	6	6	7	6	25,000
Current contingent liabilities	1	531,000	1	4	2
Current deferred revenue	3	2	7	8	9
Current operating lease liabilities	4	4	3	2	2
Total current liabilities	16	15	23	26	12
Long-term contingent liabilities	315,000	953,000	3	4	4
Deferred income taxes, net	785,000	2	11	21	21
Long-term operating lease liabilities	16	19	22	24	25
Long-term deferred revenue	0	117,000	862,000	4	5
Other long-term liabilities	78,000	86,000	30,000	46,000	0
Total liabilities	34	38	61	80	67
Commitments and Contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.0001 par value; 100,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2025 and December 31, 2024; 144,308,383 and 121,599,488 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	14,000	12,000	12,000	12,000	12,000
Additional paid-in capital	433	389	354	330	326
Accumulated other comprehensive income	12,000	27,000	50,000	9,000	—
Accumulated deficit	−166	−101	−39	11	—
Total stockholders equity	267	288	315	341	—
Total liabilities and stockholders equity	301	326	375	421	393
Common shares, shares issued (in shares)	144	122	117	115	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	22	24	19	18	16
Share-based compensation	16	21	25	18	15
Amortization of discounts on short-term investments, net	−858,000	−1	−3	−170,000	—
Deferred income taxes, net	−2	−9	−13	−6	−7
Change in estimated fair value of contingent liabilities	325,000	−3	−341,000	−592,000	1
Gain on sale of ion channel asset	−3	0	—	—	—
Other	761,000	544,000	100,000	190,000	64,000
Accounts receivable, net	189,000	−625,000	27	−13	6
Prepaid expenses and other current assets	−1	642,000	2	−5	−632,000
Other long-term assets	628,000	645,000	642,000	−788,000	1
Accounts payable, accrued expenses, and other liabilities	−231,000	−2	920,000	15	2
Operating lease liabilities	−3	−2	−563,000	2	−3
Deferred revenue	−2	−6	−5	−9	−7
Net cash used in operating activities	−36	−40	2	−4	−6
Purchases of short-term investments	−47	−40	−113	−55	0
Proceeds from maturity of short-term investments	51	78	97	0	—
Purchases of property and equipment	−565,000	−2	−2	−17	−4
Payments of contingent liabilities	0	−400,000	−4	−1	−720,000
Proceeds from sale of short-term investments	90,000	2	3	70,000	1
Proceeds from sale of ion channel asset	3	0	—	—	—
Net cash provided by investing activities	6	38	−18	−73	−4
Payments of contingent liabilities	−450,000	−75,000	−300,000	−2	−1
Proceeds from issuance of common stock from stock plans	489,000	3	1	624,000	0
Taxes paid related to net share settlement of equity awards	0	−960,000	−1	−189,000	—
Proceeds from issuance of common stock in private placement, net of commissions	28	0	—	—	12
Proceeds from issuance of common stock under ATM facility, net of commissions	0	11	0	96	0
Payment of transaction costs	−324,000	−571,000	−473,000	−4	—
Net cash provided by financing activities	28	13	−892,000	111	10
Net increase (decrease) in cash, cash equivalents, and restricted cash	−2	11	−17	34	0
Right-of-use assets obtained in exchange for lease obligations:	0	39,000	328,000	10	15
Deferred revenue recorded in accounts receivable	2	732,000	517,000	942,000	11
Purchase of fixed assets recorded in accounts payable	47,000	77,000	667,000	22,000	1
Transaction cost recorded in accounts payable	0	15,000	370,000	473,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro